deltatrials
Completed PHASE4 INTERVENTIONAL 1-arm NCT02047006

Dose-finding of Rivaroxaban in Hemodialysis

Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients

Sponsor: AZ Sint-Jan AV

Conditions Chronic Renal Failure
Interventions Rivaroxaban 10 mg
Updated 6 times since 2017 Last updated: Jan 13, 2015 Started: Sep 30, 2013 Primary completion: Feb 28, 2014 Completion: Oct 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Chronic Renal Failure, this trial is completed. The trial is conducted by AZ Sint-Jan AV and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AZ Sint-Jan AV
  • Onze Lieve Vrouw Hospital
Data source: AZ Sint-Jan AV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations